Clinicopathological comparison between PTCL‐TBX21 and PTCL‐GATA3 in Japanese patients
Cancer Medicine · 2024
DOI: 10.1002/cam4.6793 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yasumasa Shimasaki und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, Kurume University, Kurume, Japan. Hauptthemen laut MEDLINE: Algorithms, Lymphoma, T-Cell, Peripheral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
Peripheral T‐cell lymphoma not otherwise specified (PTCL‐NOS) is a heterogeneous disease that can be classified into the PTCL‐TBX21 and PTCL‐GATA3 subtypes.
Methods
In this study, we compared the clinicopathological features of PTCL‐NOS in a Japanese cohort, classified using an IHC algorithm.
Results
One hundred patients with PTCL‐NOS were categorized as having PTCL‐TBX21 ( n = 55), PTCL‐GATA3 ( n = 24), or PTCL‐unclassified ( n = 21). When comparing PTCL‐TBX21 and PTCL‐GATA3, PTCL‐TBX21 showed significantly lower CD4 positivity ( p = 0.047), lower counts of high endothelial venules ( p = 0.032), and a tendency for a better response to initial treatment ( p = 0.088). Gene expression analysis using the nCounter system showed higher expression of tumor immunity‐related genes, such as PD‐L1, LAG3, and IDO1, in PTCL‐TBX21 than in PTCL‐GATA3. PTCL‐GATA3 had significantly worse overall survival (OS) than those with PTCL‐TBX21 ( p = 0.047), although a similar tendency was observed for progression‐free survival (PFS) ( p = 0.064). PTCL‐GATA3 was a prognostic factor for OS in univariate analysis (HR 2.02; 95% CI, 1.09–3.77; p = 0.027), although multivariate analysis did not show significance (HR 2.07; 95% CI, 0.93–4.61; p = 0.074). In the PFS analysis, PTCL‐GATA3 was an independent prognostic factor by univariate analysis (HR 1.96; 95% CI, 1.08–3.56; p = 0.027) and multivariate analysis (HR 2.34; 95% CI, 1.07–5.11; p = 0.032).
Conclusion
The classification of PTCL‐NOS into PTCL‐TBX21 and PTCL‐GATA3 is useful for predicting the prognosis of Japanese patients and stratifying the administration of tumor immune checkpoint inhibitors in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Medicine, Kurume University, Kurume, Japan.
- Department of Hematology, Shimane University Hospital, Izumo, Japan.
- Department of Hematology, Endocrinology, and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
- Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan.
- Department of Hematology, Chiba University Hospital, Chiba, Japan.
- Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan.
ORCID-Profile: Hiroaki Miyoshi, Mayuko Moritsubo, Yoshitaka Imaizumi
Zitieren
APA
Shimasaki, Y., Miyoshi, H., Kawamoto, K., Yoshida, N., Mishina, T., Nakashima, K., Imamoto, T., Sugio, T., Yanagida, E., Kato, T., Yamada, K., Takeuchi, M., Suzuki, T., Moritsubo, M., Furuta, T., Imaizumi, Y., Takizawa, J., Kato, K., Suzumiya, J., …, & Ohshima, K. (2024). Clinicopathological comparison between PTCL‐TBX21 and PTCL‐GATA3 in Japanese patients. Cancer Medicine. https://doi.org/10.1002/cam4.6793
Vancouver
Shimasaki Y, Miyoshi H, Kawamoto K, Yoshida N, Mishina T, Nakashima K, et al. Clinicopathological comparison between PTCL‐TBX21 and PTCL‐GATA3 in Japanese patients. Cancer Medicine. 2024. doi:10.1002/cam4.6793
BibTeX
@article{Shimasaki2024,
author = {Shimasaki, Yasumasa and Miyoshi, Hiroaki and Kawamoto, Keisuke and Yoshida, Noriaki and Mishina, Tatsuzo and Nakashima, Kazutaka and Imamoto, Teppei and Sugio, Takeshi and Yanagida, Eriko and Kato, Takeharu and Yamada, Kyohei and Takeuchi, Mai and Suzuki, Takaharu and Moritsubo, Mayuko and Furuta, Takuya and Imaizumi, Yoshitaka and Takizawa, Jun and Kato, Koji and Suzumiya, Junji and Suzuki, Ritsuro and Ohshima, Koichi},
title = {Clinicopathological comparison between PTCL‐TBX21 and PTCL‐GATA3 in Japanese patients},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.6793}
}
EUVIMED